Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials.

Mangal, Naveen; Salem, Ahmed Hamed; Menon, Rajeev M; Freise, Kevin J

Mangal, Naveen; Salem, Ahmed Hamed; Menon, Rajeev M; Freise, Kevin J.

Afiliação

Mangal N; Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, FL, USA.
Salem AH; Abbvie, Inc., North Chicago, IL, USA.
Menon RM; Abbvie, Inc., North Chicago, IL, USA.
Freise KJ; Abbvie, Inc., North Chicago, IL, USA.

Hematol Oncol ; 2018 Apr 19.

Article em En | MEDLINE | ID: mdl-29672885

Palavras-chave

meta-analysis; multiple myeloma; progression-free survival; response rates; surrogate endpoints

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Revista: Hematol Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google